Philip Sunshine

Publication Details

  • REFRACTORY HYPOXEMIA ASSOCIATED WITH NEONATAL PULMONARY-DISEASE - USE AND LIMITATIONS OF TOLAZOLINE JOURNAL OF PEDIATRICS Stevenson, D. K., KASTING, D. S., Darnall, R. A., Ariagno, R. L., Johnson, J. D., MALACHOWSKI, N., BEETS, C. L., Sunshine, P. 1979; 95 (4): 595-599

    Abstract:

    Thirty-nine critically ill infants with pulmonary disease received tolazoline because of severe hypoxemia refractory to administration of 100% O2 and mechanical ventilation. Twenty-seven (69%) of the infants responded with an increase in PaO2 greater than or equal to 20 torr in the first umbilical arterial gas after completion of the initial ten-minute infusion (1 to 2 mg/kg) of the drug. A response was not correlated with survival. The overall survival was 46%, essentially unchanged from our previous report (44%). Infants with hyaline membrane disease had the poorest survival rate (33%). Complications associated with the use of tolazoline occurred in 82% of the infants. A hypotensive reaction, defined as a 25% decrease in mean arterial pressure from the pre-tolazoline level, occurred in 67% of the infants, and more commonly in the infants with RDS (87%). In 11 infants who did not respond to the initial dose of tolazoline, the dose was increased up to 10 mg/kg/hour; only one infant responded, and eight (73%) had a hypotensive reaction.

    View details for Web of Science ID A1979HN82900024

    View details for PubMedID 480041

Stanford Medicine Resources:

Footer Links: